The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...
Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Pathologist Dr Margot Bolster said Breeda O’Donoghue's death should be referred to the Health Products Regulatory Authority ...
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback